Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Kjekshus

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Journal of Cardiac Failure|April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
JACC. Heart Failure|March 14, 2014
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)Ana Cristina Perez, Pardeep S Jhund, David J Stott, et al.
European Journal of Heart Failure|March 15, 2013
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trialsThor Ueland, Ståle H Nymo, Roberto Latini, et al.
European Journal of Heart Failure|May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)Sally C Inglis, John J V McMurray, Michael Böhm, et al.
JAMA Cardiology|December 16, 2020
Assessing the Role of Rare Genetic Variation in Patients With Heart FailureGundula Povysil, Olympe Chazara, Keren J Carss, et al.
BMC Medical Genetics|December 22, 2014
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)Vincent G Haver, Niek Verweij, John Kjekshus, et al.
European Journal of Heart Failure|January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptideHans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure|December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trialPaula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
JACC. Heart Failure|June 23, 2014
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)Jennifer K Rogers, Pardeep S Jhund, Ana-Cristina Perez, et al.
Journal of the American College of Cardiology|October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Journal of Cardiac Failure|April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
JACC. Heart Failure|March 14, 2014
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)Ana Cristina Perez, Pardeep S Jhund, David J Stott, et al.
European Journal of Heart Failure|March 15, 2013
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trialsThor Ueland, Ståle H Nymo, Roberto Latini, et al.
European Journal of Heart Failure|May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)Sally C Inglis, John J V McMurray, Michael Böhm, et al.
JAMA Cardiology|December 16, 2020
Assessing the Role of Rare Genetic Variation in Patients With Heart FailureGundula Povysil, Olympe Chazara, Keren J Carss, et al.
BMC Medical Genetics|December 22, 2014
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)Vincent G Haver, Niek Verweij, John Kjekshus, et al.
European Journal of Heart Failure|January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptideHans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure|December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trialPaula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
JACC. Heart Failure|June 23, 2014
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)Jennifer K Rogers, Pardeep S Jhund, Ana-Cristina Perez, et al.
Journal of the American College of Cardiology|October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Pageof 12